Document Detail


Polymyositis with respiratory muscle weakness requiring mechanical ventilation in a patient with metastatic thymoma treated with octreotide.
MedLine Citation:
PMID:  10509161     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Although most patients with thymoma present with a mediastinal mass amenable to surgical resection, some patients develop metastatic disease requiring systemic therapy. The majority of thymomas express somatostatin receptors as demonstrated by octreotide scanning, an observation which has prompted the clinical use of octreotide in patients with this disease. Many patients with thymoma exhibit autoimmune paraneoplastic syndromes, most frequently myesthenia gravis. We report here the case of a patient with metastatic thymoma who developed a profound autoimmune polymyositis and lupus-like syndrome that flared following treatment with octreotide and was associated with a clinical response to this agent. No evidence for myesthenia gravis was discovered. The severity of the myopathy necessitated mechanical ventilation for 12 weeks. The natural history of thymoma, treatment options including recent combination chemotherapy regimens, and potential mechanisms for flaring of autoimmune paraneoplastic syndromes triggered by therapy of thymoma are discussed.
Authors:
B I Rini; T F Gajewski
Publication Detail:
Type:  Case Reports; Journal Article; Review    
Journal Detail:
Title:  Annals of oncology : official journal of the European Society for Medical Oncology / ESMO     Volume:  10     ISSN:  0923-7534     ISO Abbreviation:  Ann. Oncol.     Publication Date:  1999 Aug 
Date Detail:
Created Date:  1999-11-16     Completed Date:  1999-11-16     Revised Date:  2006-04-24    
Medline Journal Info:
Nlm Unique ID:  9007735     Medline TA:  Ann Oncol     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  973-9     Citation Subset:  IM    
Affiliation:
Department of Medicine, University of Chicago, IL, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Adolescent
Antineoplastic Agents, Hormonal / adverse effects*,  therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Follow-Up Studies
Humans
Male
Muscle Fatigue
Octreotide / adverse effects*,  therapeutic use
Paraneoplastic Syndromes / diagnosis,  drug therapy
Polymyositis / chemically induced*,  therapy
Respiration, Artificial
Respiratory Muscles / drug effects,  pathology*
Thymoma / diagnosis,  drug therapy*,  physiopathology,  secondary
Thymus Neoplasms / diagnosis,  drug therapy*,  physiopathology
Tracheostomy
Chemical
Reg. No./Substance:
0/Antineoplastic Agents, Hormonal; 83150-76-9/Octreotide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation betwee...
Next Document:  A phase II study of the modulation of 5-fluorouracil and folinic acid with high-dose infusional hydr...